NCT03737994 2026-04-07
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT02393625 2026-04-02
Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
Novartis
Phase 1 Active not recruiting
NCT02584933 2026-04-02
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
Novartis
Phase 4 Active not recruiting
NCT05100134 2026-04-01
Managed Access Programs for LDK378, Ceritinib
Novartis
No longer available
NCT02780128 2026-03-10
NEPENTHE
Children's Hospital of Philadelphia
Phase 1 Terminated
NCT03501368 2026-02-27
Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02559778 2026-02-20
PEDS-PLAN
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT03611738 2026-02-09
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting